同: recombinant human erythropoietin

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 組換え造血成長因子の概要 introduction to recombinant hematopoietic growth factors
2. 慢性腎疾患における貧血のマネージメントのためのダルベポエチンアルファ darbepoetin alfa for the management of anemia in chronic kidney disease
3. Treatment of anemia in nondialysis chronic kidney disease
4. 慢性疾患／炎症時の貧血 anemia of chronic disease inflammation
5. 抗エリスロポエチン抗体による赤芽球癆 pure red cell aplasia due to anti erythropoietin antibodies

English Journal

Probing protease sensitivity of recombinant human erythropoietin reveals α3-α4 inter-helical loop as a stability determinant.

Sebastian Samuel J1, Kumar D1, Babu Chodisetti S1, Agrewala JN1, Singh B1, Guptasarma P2, Sarkar D1.
Proteins.Proteins.2015 Oct;83(10):1813-22. doi: 10.1002/prot.24865.
Although unglycosylated HuEpo is fully functional, it has very short serum half-life. However, the mechanism of in vivo clearance of human Epo (HuEpo) remains largely unknown. In this study, the relative importance of protease-sensitive sites of recombinant HuEpo (rHuEpo) has been investigated by an
PMID 26214268

Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.

Kimachi M1, Fukuma S, Yamazaki S, Yamamoto Y, Akizawa T, Akiba T, Saito A, Fukuhara S.
Nephron.Nephron.2015 Sep 8. [Epub ahead of print]
BACKGROUND: Hemodialysis (HD) patients occasionally experience minor asymptomatic elevation in C-reactive protein (CRP) levels, which may be associated with difficulty in managing renal anemia using erythropoiesis-stimulating agents (ESAs). Here, we assessed whether elevation of CRP predicts future
PMID 26344924

Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.

Wilhelm-Leen ER1, Winkelmayer WC2.
American journal of kidney diseases : the official journal of the National Kidney Foundation.Am J Kidney Dis.2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28.
BACKGROUND: Epoetin alfa (EPO) and darbepoetin alfa (DPO) are erythropoiesis-stimulating agents that are widely and interchangeably used for the treatment of anemia in patients with advanced chronic kidney disease and end-stage renal disease. No study has specifically compared the risks of hard stud
PMID 25636816

Japanese Journal

血液透析患者におけるrHuEPO製剤からエポエチンベータペゴルヘの切替え維持投与に関する検討 : 切替え時rHuEPO投与量別追加解析 (小特集新規持続型赤血球造血刺激因子製剤エポエチンベータペゴル)

宮？滋,鈴木正司
医薬ジャーナル 48(11), 114-123, 2012-11-00
NAID 40019484572

ビタミンE固定化ダイアライザによるESA投与量に関する多施設前向き研究 : VEESA-study

望月隆弘,衣笠えり子,草野英二 [他],大和田滋,久野勉,兒島憲一郎,小林修三,佐藤稔,島田憲明,中尾一志,中澤了一,西村英樹,野入英世,重松隆,友雅司,佐中孜,前田貞亮
日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 45(9), 853-862, 2012-09-28
… 12.0g/dLの範囲で，VPS-HA群はIV型PS膜群に比して良好なESA反応性を示した．とくにVPS-HA群のDarbepoetin alfa（DA）投与例では，8か月以降で開始時と比較して統計的有意差をもってERIが減少していた．またIV型PS膜群のrHuEPO投与症例では，統計的に5，7，10か月で，開始時と比較してERIが増加していた．VPS-HAとIV型PS膜の群間比較では，11か月目でVPS-HA群のDA投与例でIV型PS膜群に比して，ERIが有意に減少していた．【結語】目標Hb値11. …
NAID 10031123032

遺伝子組換えヒトエリスロポエチンによる赤血球造血刺激因子製剤療法低反応性腹膜透析患者の持続型赤血球造血刺激因子製剤 Darbepoetin Alfa 投与の効果

平松英樹,林裕樹,水野正司 [他],鈴木康弘,戸田晋,伊藤功,丸山彰一,伊藤恭彦,松尾清一
日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 45(3), 247-253, 2012-03-28
… 腹膜透析（peritoneal dialysis：PD）患者において遺伝子組換えヒトエリスロポエチン（recombinant human erythropoietin：rHuEPO）投与量は，最大24,000単位/月（12,000単位/2週または6,000単位/週）であるが，十分な貧血改善効果が得られない症例もみられる．われわれは，当院PD患者46名を対象とし，rHuEPOによりヘモグロビン値（Hb値）が，10g/dL以上に到達できなかった赤血球造血刺激因子製剤（erythropoiesis stimulation …
NAID 10030813494

Related Pictures

人红细胞生成素-α（rHuEPO-a Recombinant human erythropoietin rHuEPO Investigator Outlines Stumbling Blocks to Human EPO (rHuEPO or epoetin alfa Model of the rHuEPO–EPOR dimeric complex Chronic kidney disease: Management Figure 1: Cellular iron uptake: mechanisms rHuEPO for treatment of multiple myeloma